A Phase 1 dose-escalation trial of DSP-7888 (NCT02498665), a peptide vaccine including two synthetic peptides derived from WT1, was completed in patients with multiple malignancies (pancreatic cancers, sarcomas, non-small-cell lung cancers, ovarian cancers, and melanomas), including GBM (n = 7). Here, WT1 is linked to glioblastoma.